Giuseppe MichieliOct 11
#Antiviral efficacy of oral #ensitrelvir versus oral ritonavir-boosted #nirmatrelvir in #COVID19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial, https://etidiohnew.blogspot.com/2025/10/antiviral-efficacy-of-oral-ensitrelvir.html
#Antiviral efficacy of oral #ensitrelvir versus oral ritonavir-boosted #nirmatrelvir in #COVID19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial

Giuseppe MichieliApr 26, 2024

Sporadic Occurrence of #Ensitrelvir #Resistant #SarsCoV2 #Japan, Emerg Infect Dis.: https://wwwnc.cdc.gov/eid/article/30/6/24-0023_article

Using the GISAID EpiCoV database, we identified 256 #COVID19 patients in Japan during March 31–December 31, 2023, who had mutations in the SARS-CoV-2 #NS5 conferring ensitrelvir resistance.

Sporadic Occurrence of Ensitrelvir-Resistant SARS-CoV-2, Japan

Sporadic Occurrence of Ensitrelvir-Resistant SARS-CoV-2, Japan

Emerging Infectious Diseases journal
Show threadGiuseppe MichieliJul 15, 2023
''#Ensitrelvir #treatment of hamsters infected with the virus possessing Nsp5-M49L/E166A was ineffective; however, #nirmatrelvir or #molnupiravir treatment was effective. Therefore, it is important to closely monitor the emergence of ensitrelvir-resistant SARS-CoV-2 variants to guide antiviral treatment selection.''
Giuseppe MichieliJul 15, 2023
In vitro and in vivo characterization of #SARS-CoV-2 #resistance to #ensitrelvir https://www.nature.com/articles/s41467-023-40018-1 #antivirals #research #science #pharmacology
In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvir - Nature Communications

Ensitrelvir is an oral antiviral agent that targets SARS-CoV-2 and is clinically useful against infection with omicron variants. The authors characterized mutant viruses with reduced sensitivity to ensitrelvir in vitro and in vivo.

Nature
PeterD 🇩🇪 🇨🇦Mar 6, 2023
COVID pill is first to cut short positive-test time after infection
https://www.nature.com/articles/d41586-023-00548-6
"The antiviral ensitrelvir, which is not approved in the United States, shortens symptoms in people with mild COVID and might reduce risk of long COVID — but more data are needed."
#Covid #Ensitrelvir #LongCovid
COVID pill is first to cut short positive-test time after infection

The antiviral ensitrelvir, which is not approved in the United States, shortens symptoms in people with mild COVID and might reduce risk of long COVID — but more data are needed.

Giuseppe MichieliFeb 10, 2023
#Efficacy #comparison of #3CLpro #inhibitors #ensitrelvir and #nirmatrelvir against #SARS-CoV-2 in vitro and in vivo https://academic.oup.com/jac/advance-article/doi/10.1093/jac/dkad027/7033725?rss=1
Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo

AbstractObjectives. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become established in the human population, making the need to develop safe

OUP Academic
Show thread杂食型蓑白（赛里斯地区的形态）Dec 26, 2022

#补个来源

#上海医药 获得抗新冠病毒口服药物#Ensitrelvir 独家进口及经销权
https://company.cnstock.com/company/scp_gsxw/202212/4997431.htm

新冠口服药！#盐野义 3CL蛋白酶抑制剂#Xocova 获日本紧急批准：治疗轻中度COVID-19!
https://news.bioon.com/article/3eade499910e.html

上海医药获得抗新冠病毒口服药物Ensitrelvir独家进口及经销权-上市公司-上海证券报·中国证券网

　　上海医药12月23日晚间公告称，公司全资子公司上海控股有限公司（简称“上药控股”）与平安盐野义就抗新冠病毒口服药物Ensitrelvir的进口品签订了《进口分销协议》，上药控股将作为Ensitrelvir进口品在中国大陆地区的独家进口商和经销商。同时，上海医药与平安盐野义就更广泛的新药和仿制药产品在更深远的合作层面签订了《战略合作框架协议》。　　公告